Home Blog Page 23

FGR advances carbon fibre commercialisation with Aeropreg agreement

Highlights

  • First Graphene enters Development and Commercialisation Agreement with global prepreg manufacturer Aeropreg to develop graphene-enhanced carbon fibre prepreg
  • Three-year agreement builds on positive results from First Graphene’s development work incorporating PureGRAPH® into carbon fibre composites
  • Collaboration combines PureGRAPH® and proprietary epoxy concentrates with Aeropreg’s established manufacturing and resin development capabilities
  • First Graphene intends to progress the graphene-enhanced prepreg product towards commercial launch through Aeropreg’s existing sales channels
  • Partnership solidifies FGR’s pathway into the global carbon fibre reinforced plastics market, estimated to grow to US$43.7 billion by 2033

SYDNEY, Oct. 5, 2026 /PRNewswire/ — First Graphene Limited (ASX: FGR; “First Graphene” or “the Company”) (FRA:M11) (OTCQB:FGPHF) has entered a three-year Development and Commercialisation Agreement with Turkish prepreg manufacturer, Aeropreg, to advance a PureGRAPH® enhanced carbon fibre prepreg towards commercialisation.

Under the three-year agreement, First Graphene’s proprietary epoxy concentrates will be used to optimise the incorporation of PureGRAPH® into Aeropreg’s existing carbon fibre prepreg manufacturing process.

Carbon fibre prepreg is a composite material that has been pre-infused with partially cured polymer resin and is often used to strengthen components used in aerospace, defence, automotives and sporting goods.

The development program will focus on achieving controlled and repeatable graphene loading within prepreg before validating the strength, durability, performance and manufacturability of the resulting material.

Subject to trial results, First Graphene and Aeropreg will advance the material towards commercial launch, leveraging Aeropreg’s existing sales channels across the aerospace, automotive, marine and sporting goods industries.

The new partnership represents the next stage in First Graphene’s strategy to convert its technical development in carbon fibre composites into commercial opportunities for PureGRAPH®.

It also follows First Graphene’s track record of positive results from customer development programs and grant-funded research on graphene-enhanced carbon fibre composites.

Securing a commercial prepreg solution and an experienced manufacturing partner is an essential step towards addressing defence, aerospace and automotive applications. Modern commercial aircraft make extensive use of carbon fibre prepreg in their airframes, for primary structures.

The collaboration aligns with First Graphene’s increased focus on the US market and its recent acquisition of MITO Materials, which expanded the Company’s composites technology and customer relationships in North America.

Importantly, Aeropreg has in-house resin development and testing capabilities, providing First Graphene with a manufacturing partner to advance this technology towards commercial production.

This agreement provides First Graphene with a potential pathway into the global carbon fibre reinforced plastics market, which is estimated to grow to the value of US$43.7 billion by 2033[1].

About Aeropreg

Aeropreg manufactures and supplies prepreg composite materials, including carbon, glass, aramid and basalt fibre prepregs, for aerospace, automotive, marine, sporting goods, medical and wind energy applications. The company offers customised material solutions and technical support to meet customers’ specific requirements.

Aeropreg’s research and development capabilities include developing and refining resin systems, supported by in-house chemical, physical, thermal and mechanical testing.

Aeropreg is a subsidiary of Spinteks. According to Aeropreg, its prepreg production operates under AS9100 aerospace quality management certification. In June 2026, Spinteks was added to the Turkish Aerospace (TUSAŞ) Approved Supplier List for composite manufacturing, with Aeropreg carrying out prepreg production within the group.[2]

First Graphene Managing Director and CEO, Michael Bell, said:

“The new partnership with Aeropreg represents an important step in progressing our carbon fibre development work towards commercialisation in key industries such as aerospace and defence.

We have built considerable knowledge around incorporating PureGRAPH® into composite materials and the next step was to combine that expertise with an established manufacturer capable of producing and taking a product to market.

Aeropreg brings extensive prepreg manufacturing and resin development capabilities, as well as established global sales channels across a number of high-value industries.

Our immediate focus will be on successfully validating the material within Aeropreg’s manufacturing process, with the longer-term objective of establishing another commercial route to market for PureGRAPH®.”

-Ends-

This announcement has been approved by the Chairman.

References

 

Tigerair Taiwan Expands Its Network With New Connected Travel Platform, Powered by Dohop

With Scoot as its first airline partner, tigerhop expands Dohop’s footprint in Asia and adds new network capacity and destinations for Taiwan’s leading low-cost carrier.

REYKJAVÍK, Iceland, Oct. 5, 2026 /PRNewswire/ — Dohop, the travel technology company creating a new standard for Connected Travel that works beyond traditional interline, has announced a new partnership with Tigerair Taiwan to deploy the Dohop-powered tigerhop platform, now live on the airline’s retail channels. Through the initial partnership with Scoot, Singapore Airlines’ low-cost subsidiary, Tigerair Taiwan customers will have more options for travel within Asia, specifically across North Asia routes and new connections to Singapore, all bookable in a single transaction.

Tigerair Taiwan Launches tigerhop, a Dohop-powered Connected Travel Platform
Tigerair Taiwan Launches tigerhop, a Dohop-powered Connected Travel Platform

Tigerhop, powered by Dohop’s RetailConnect platform, allows Tigerair Taiwan to sell multi-carrier journeys that combine its own flights with onward services operated by partner airlines. At launch, tigerhop will offer connections from Taipei and Da Nang to Singapore via Scoot, and travelers departing from Singapore can transfer at Taoyuan International Airport to other destinations, including Akita, Hanamaki, and Tottori.

“Tigerair Taiwan demonstrates how airlines can use Connected Travel to expand their network without the cost and complexity of bilateral interlining,” said Hugh Aitken, Chief Operating Officer at Dohop. “Launching tigerhop with Scoot gives Taiwanese travellers access to more destinations through Tigerair Taiwan’s own channels, while enabling the airline to capture bookings that might otherwise go to OTAs. With additional carriers joining the platform in the coming months, tigerhop also marks an important expansion of Dohop’s presence in Asia.”

For Tigerair Taiwan, the partnership adds connections with other carriers without complex interline or codeshare agreements, expanding its commercial reach with minimal technical investment. By selling these itineraries through tigerhop under its own brand, the airline can compete more effectively with online travel agents while giving passengers access to Dohop’s ConnectSure disruption support and travel protection services.

“Working with Dohop, we can grow our international reach without traditional interline structures while maintaining our brand promise to our passengers,” said Joyce Huang, Chairperson of Tigerair Taiwan. “We look forward to partnering with new carriers and expanding our coverage in the APAC region through Dohop’s technology.”

The Tigerair Taiwan launch extends Dohop’s presence across Asia, where its platforms are already live for Scoot, Thai Vietjet, Citilink and Air India Express, with others in development. These deployments reflect growing demand among Asian carriers for flexible connectivity that can integrate into existing retail channels without individual codeshare or bilateral interline agreements, supporting the industry’s broader move toward modular, multi-carrier connectivity and modern retailing.

For more information about the partnership between Dohop and Tigerair Taiwan, or to arrange an interview with a Dohop executive, please contact Vanessa Horwell at vhorwell@thinkinkpr.com.

About Dohop 
Dohop enables connected journeys from booking through arrival, combining flights and travel segments from multiple airlines and travel providers into a single trip supported by disruption handling, travel protection, and baggage transfer. More than 100 airlines and travel partners, including Air France, Air Transat, easyJet, Scoot, Vueling and Wizz Air, use Dohop’s Connected Travel platform to create, sell, and support multi-carrier journeys without traditional interline agreements, expanding network connectivity and route options as participation grows. Visit www.dohop.com/airlines to learn more.

About Tigerair Taiwan
Tigerair Taiwan launched its first route in 2014. As Taiwan’s first and only low-cost carrier (LCC), it operates routes across Asia, providing travelers with affordable, reliable, and convenient options. Focusing on a warm, passionate, and genuine service while upholding safety as its core value, Tigerair Taiwan continues to expand its footprint and add more destinations in Asia. Learn more at www.tigerairtw.com.

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared

MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.

Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and anti-fibrotic effects to potentially prevent and reverse organ damage in ANCA-associated vasculitis (AAV) and numerous other kidney, liver and lung diseases. The ongoing phase 2 trial is designed to translate these mechanistic effects into meaningful clinical impact.  

The collaboration brings together Alentis’ scientific expertise as the leading clinical-stage biopharmaceutical company targeting claudin-1 and CSL’s global development and commercialisation capabilities in nephrology, with a shared goal of bringing innovative and highly impactful treatment options to patients with rare kidney and liver diseases. In addition to AAV-RPGN, the two companies will advance lixudebart as a novel treatment for focal segmental glomerulosclerosis (FSGS), a rare progressive kidney disease, and for primary sclerosing cholangitis (PSC), an autoimmune chronic liver disease.

“This partnership enables us to dramatically accelerate the development of lixudebart in several indications in parallel,” said Dr Mark Pruzanski, Chief Executive Officer of Alentis Therapeutics. “We are convinced CSL’s demonstrated clinical development and commercialisation capabilities in AAV and kidney diseases makes them the right partner to bring lixudebart to patients. More broadly, this furthers the validation of claudin-1 as a novel therapeutic target and we are excited about the potential to accelerate the advancement of our other clinical stage assets and preclinical pipeline.”

“Patients diagnosed with ANCA-associated vasculitis with rapidly progressive glomerulonephritis face rapid kidney function decline, leaving them at risk of irreversible damage even with currently available treatments,” said Dr Bill Mezzanotte, EVP, Head of R&D, CSL. “We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease, first in AAV-RPGN and hopefully also in focal segmental glomerulosclerosis, while potentially showing similar benefit on liver function in primary sclerosing cholangitis. Our partnership with Alentis reflects CSL’s commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships.”

Under the agreement, CSL and Alentis will jointly develop and co-promote lixudebart. CSL will make an initial payment to Alentis of US$355 million, with Alentis eligible to receive up to an additional US$1.2 billion in commercial milestone payments. In addition to these payments, CSL will fully fund the completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial in AAV-RPGN, the Phase 2 trials in FSGS and PSC and other supporting development activities. Once commercialised, global profits will be shared 55 per cent to CSL and 45 per cent to Alentis.

About AAV-RPGN
ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN) is a rare, severe and potentially fatal autoimmune disease in which the body’s immune system attacks small blood vessels in the kidney. RPGN is characterized by rapid loss of kidney function over a very short period (days to weeks). Despite potent immunosuppressive treatment, most patients develop significant or total loss of kidney function.

About Lixudebart
Lixudebart (formerly known as ALE.F02) is an investigational monoclonal antibody that selectively targets exposed claudin-1, a key driver of inflammatory and fibrotic signalling pathways in numerous fibrotic diseases of the kidney, liver, lung, intestine and other solid organs. In an interim analysis of 26 patients with AAV-RPGN in the ongoing Phase 2 RENAL trial, lixudebart showed promising improvement in kidney function as assessed by eGFR and proteinuria at 24 weeks. In the Phase 1b FEGATO trial in 41 patients with advanced F3/F4 liver fibrosis, lixudebart demonstrated improved liver function at 6 weeks. In both studies lixudebart showed dose-dependent claudin-1 target engagement, along with a favourable safety and tolerability profile. Lixudebart has been granted Orphan Drug designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs almost 29,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

About Alentis
Alentis is a clinical-stage, privately held biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. Beyond the company’s lead antibody for fibrosis, lixudebart, Alentis is developing oncology candidates ALE.P02 and ALE.P03. These are claudin-1 targeted ADCs with a tubulin inhibitor payload and topoisomerase‑I inhibitor payload, respectively. ALE.P02 was granted Fast Track designation by FDA for the treatment of advanced or metastatic claudin-1 expressing squamous cancers, irrespective of the organ of origin. Both ADCs are currently in Phase 1/2 studies enrolling patients with a variety of solid tumor types.

Alentis was founded on the groundbreaking research in the laboratory of Prof. Thomas Baumert, MD, at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). The company is headquartered in Basel, Switzerland. Visit www.alentis.ch

“Future Resonance — ShanghaiEye Night” Brings Shanghai to Washington, Fosters People-to-People Exchange Across the Pacific

WASHINGTON, Oct. 4, 2026 /PRNewswire/ — On October 3, 2026, local time, a Shanghai-themed cultural exchange event was held on the National Mall in Washington, D.C., bringing a taste of Shanghai to the U.S. Titled “Future Resonance — ShanghaiEye Night,” the event was also part of the “Shanghai Let’s Meet” city promotion initiative and a broader series of China-U.S. people-to-people exchanges. Through a variety of cultural activities and interactions, the event built bridges between people across the Pacific and offered a glimpse of Shanghai as an open, inclusive and dynamic international metropolis.

"Future Resonance — ShanghaiEye Night" China-U.S. people-to-people exchange events held in Washington D.C. Photo: Shanghai Media Group
“Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange events held in Washington D.C. Photo: Shanghai Media Group

The event, held by Shanghai Media Group, brought together nearly 100 prominent figures from China and the United States across the political, business, technology, cultural and arts sectors. Song Jiongming, President of Shanghai Media Group, and Susan Lee, Secretary of State of Maryland, attended the event and delivered remarks. Chinese Ambassador to the United States Xie Feng was also in attendance.

In the afternoon, the National Mall was transformed into a “mini Shanghai” carnival. The carnival featured 50 stalls showcasing international cuisine, a “Shanghai Charm” themed exhibition area and displays of China’s intangible cultural heritage.

Visitors got a glimpse of Shanghai’s cutting-edge technological innovation through a model of the C919 passenger jet, explored the city’s latest trends through a model of the Oriental Pearl Tower and popular Chinese cultural and creative IPs, and took a virtual journey through Shanghai’s past and present with VR headsets provided by the Shanghai Museum. Time-honored brands such as White Rabbit candy, Hero fountain pens and Lao Feng Xiang offered visitors a taste of Shanghai’s iconic homegrown brands. Meanwhile, an IP SHANGHAI lenticular art exhibition brought the city to life through dynamic images that changed as visitors moved around the displays.

From such an immersive experience showcasing Shanghai as a first stop for international visitors entering China to distinctive IPs spanning culture, commerce, tourism, sports and exhibitions, the carnival offered Americans and international visitors a glimpse of the city and a chance to experience Shanghai firsthand at one of Washington’s most iconic landmarks. Many visitors said they hoped to visit Shanghai in person and explore the city on foot through a “city walk.”

As the sun began to set, its golden glow fell over the Capitol dome. Against an iconic backdrop featuring the two cities, the “Future Resonance” outdoor concert got underway.

Young performers from China and the United States took the stage alongside renowned artists from both countries. The One Voice Children’s Choir from the United States and the Manhattan Philharmonic joined forces to perform “We Are Together,” a song created in Shanghai to celebrate friendship between the two countries.

The program featured a rich mix of symphonic works, traditional Chinese music, Chinese opera and anime music. Footage from Shanghai’s city image film “UP! SHANGHAI” played on the large screen behind the stage throughout the concert.

Later that evening, nearly 100 guests from China and the United States, including prominent figures from politics, business, technology, culture and the arts, took part in the ShanghaiEye Night dialogue session.

Themed “Invest in China for a Win-Win Future,” the dialogue highlighted the China International Import Expo and Shanghai’s development as an international economic, financial, trade, shipping and technological innovation center. It also showcased the city’s world-class business environment and provided a platform for high-level dialogue and practical cooperation between Chinese and U.S. companies.

The dialogue also featured a “Shanghai Charm” city image reception area. On one side, twenty selected historical photographs capturing key “Shanghai moments” in China-U.S. relations were displayed, including the signing of the Shanghai Communiqué, the launch of the first China-U.S. air route, the opening of Apple’s first store in China, the Tesla Gigafactory and the 10th anniversary of Shanghai Disney Resort.

On the other side, 20 photographs from the IP SHANGHAI platform, under the theme “Chasing Dreams in Shanghai,” showcased Lujiazui Financial City, Yangshan Deep-Water Port, Shanghai Grand Opera House, the North Bund shipping hub, and the Huangpu River and Suzhou Creek. Together, the displays offered guests a visual introduction to the city and created lasting memories of Shanghai.

With the support of the Information Office of the Shanghai Municipal Government and co-hosted by Shanghai Media Group, the World Intangible Cultural Heritage Conservation Center and the Washington Chinese Community Alliance, the event brought together guests from a range of sectors in China and the United States.

The event brought Shanghai closer to American audiences and the international community through city promotion, cultural performances, interactive experiences and high-level dialogue. It also provided a platform for people-to-people and cultural exchange between China and the United States. Reflecting the theme “Future Resonance,” the event hoped to give a warm and positive boost to people-to-people exchanges between the two countries.

Chinese performers present Peking Opera at the “Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange event in Washington, D.C.
Chinese performers present Peking Opera at the “Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange event in Washington, D.C.

Dr Maye Musk, author, supermodel, and dietitian, speaks at the Prudential Leadership Forum

Shares perspectives on leadership, resilience and legacy with nearly 1,000 customers, young professionals, and aspiring leaders


HONG KONG SAR – Media OutReach Newswire – 4 October 2026 – Prudential Hong Kong Limited (“Prudential”) welcomed Dr Maye Musk, a globally renowned author, supermodel and dietitian, to the Prudential Leadership Forum, titled Beyond Success: The Blueprint for Leadership, Resilience and Legacy, held on 3 October 2026.

(From left) Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited; Dr Maye Musk; and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc, at the Prudential Leadership Forum, where they shared perspectives on leadership, resilience and legacy planning across generations.
(From left) Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited; Dr Maye Musk; and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc, at the Prudential Leadership Forum, where they shared perspectives on leadership, resilience and legacy planning across generations.

Nearly 1,000 VIP customers, young professionals, aspiring leaders and top-performing financial consultants came together for a conversation on resilience, reinvention and the values that shape lasting family legacies.

Opening the forum, Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited, highlighted Prudential’s commitment to customers: “Prudential has earned enduring trust with families by actively listening to their evolving needs across generations. Sustaining that trust requires a forward-looking vision, creating meaningful opportunities for customers to connect with visionary leaders and fresh perspectives. Dr Maye Musk’s journey is a powerful reminder that experience, resilience and ambition can open new possibilities at every stage of life. ”

The centerpiece of the day was an engaging fireside chat between Dr Musk and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc. Through the exchange, Dr Musk shared candid reflections on rebuilding her career across life stages and countries, empowering her three children to pursue their distinct ambitions, and wealth succession.

Reflecting on her journey, Dr Musk said: “Success is rarely a straight line. Throughout my life, I have had to start over, adapt and embrace new opportunities, often when others thought it was too late. What I have learned is that resilience is built through action, not certainty. Whether as a parent, a professional or a leader, our role is not to create a perfect path for the next generation, but to give them the confidence, values and independence to create their own. Lasting legacies are built not by removing challenges, but by helping others develop the strength to navigate them.”

Angel highlighted Prudential’s vision for legacy: “In today’s rapidly evolving world, planning for the next generation is about more than passing on financial wealth. It is also about passing on the values and judgement that help them make informed decisions and pursue their aspirations. When families pair clear principles with the confidence to make their own choices, they can protect what they have built while creating a stronger foundation for generations to come. Prudential supports families in planning ahead, passing on their wealth with confidence, and building a brighter tomorrow.”

Building on the theme of preparing for the future, the forum then turned to the city’s distinctive advantages and emerging opportunities for talent through a panel discussion titled Hong Kong: Where Global Wealth and Talent Converge. Felix Chan, the Director of Hong Kong Talent Engage; and Jason Fong, Global Head of Family Office at Invest Hong Kong shared perspectives on how the leaders of tomorrow can learn, grow and thrive in Hong Kong.

By bringing together forward-looking perspectives and opportunities to engage with global leaders, Prudential continues to support customers at every stage of life, helping them plan for their health and financial wellbeing, protect what matters most, and build resilience for the future. This commitment is also reflected in value-added platforms such as PruNextGen, through which we support families in planning early for their children’s future, broadening their horizons and laying the foundations for lifelong success.

Hashtag: #PrudentialLeadershipForum

The issuer is solely responsible for the content of this announcement.

About Prudential Hong Kong Limited

Prudential has been serving the people of Hong Kong since 1964. Through Prudential Hong Kong Limited and Prudential General Insurance Hong Kong Limited, the Company provides a range of financial planning services and products, including individual life insurance, investment-linked insurance, retirement solutions, health and medical protection, general insurance, and employee benefits to protect over 1.41 million customers in Hong Kong. Beyond Hong Kong, Prudential serves the Macau community through its branch, offering health insurance and financial solutions to complete its footprint in the Greater Bay Area. Visit for more information.

Blokees Debuts 90+ New Products at Wonder Festival Shanghai 2026

SHANGHAI, Oct. 4, 2026 /PRNewswire/ — From October 3 to 4, Assembly Character Toys Brand Blokees exhibited at Wonder Festival Shanghai 2026, featuring nearly 500 products across its two core categories, Blokees Model Kits and BLOKEES WHEELS. More than 90 new products made their debut, highlighting Blokees’ continued expansion across product categories, IPs and consumer segments.


The Blokees Model Kits portfolio covers hero collecting, model kit collecting, animal-themed products and fashion-oriented products, featuring more than 10 global IPs including ULTRAMAN, TRANSFORMERS, Saint Seiya, Evangelion and DC. Products for collectors aged 16 and above were a key focus, with nearly 40 products exhibited across Champion, Champion Lite, Fantastic and Legend series , including more than 20 new products making their debut. Notably, DC made its first commercial appearance in the Legend series.

Blokees continues to expand its product ecosystem. Blokees also exhibited the latest products from its TERRAVENTURE Series and DaaLaMode Series. The TERRAVENTURE Series features animal-themed model kits based on Jurassic World, while the DaaLaMode Series combines assembly, articulation, and fashion play, expanding Blokees’ offerings across different consumer segments.

In the Blokees Wheels category, Blokees exhibited its C, E, and S Series, featuring IPs including Transformers, Ultraman, and Batman. New products based on Cyberpunk 2077, Fast & Furious × Ford and Fast & Furious × Dodge were also exhibited for the first time, further expanding the category’s offerings for vehicle enthusiasts.

Beyond products, Blokees also exhibited winning works from the “Dawn” and “Awakening” seasons of the 2026 BFC Creation Contest. Through BFC, Blokees connects players worldwide through creation and sharing, with the community now spanning 21 countries and regions.

Blokees will continue to strengthen its two core categories and expand its global product and creator ecosystem under its strategy of “Universally appealing, Stepwise pricing, Globally promoting.”

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026

MILAN, Oct. 4, 2026 /PRNewswire/ — At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented “See More, Act Earlier,” connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: “See More: Beyond Glucose,” covering glucose, ketone and combined monitoring; “Act Earlier: From Insight to Intervention,” exploring multimodal sensing and insulin delivery; and “Go Further: Realizing the Unimagined,” looking toward broader biosensing applications.

The vision was further explored at the SiBionics industry symposium, “From Sensors to Integrated Care: Emerging Technologies Shaping the Future of Diabetes Management.” The symposium was chaired by Prof. Mark Evans, of the University of Cambridge and Cambridge University Hospitals, United Kingdom, and Dr. Guido Freckmann, of the Institute for Diabetes-Technology GmbH (IfDT), Germany.

Prof. Karolina Kędzierska-Kapuza discussed CGM and individualized care in type 3c diabetes. Prof. Wei Qiang presented CGM accuracy findings and future multimodal sensing concepts. Prof. Andrej Janež explored continuous ketone monitoring in the GLP-1 era. Prof. Ahmad Haidar presented ketone monitoring research and the first findings of the SMART02 feasibility study on integrated glucose sensing and insulin delivery.

SMART02 evaluated an early prototype of niia signature, an investigational device jointly developed by PharmaSens and SiBionics since the two companies announced their collaboration in June 2025. niia signature will combine continuous glucose monitoring (CGM), insulin delivery and an automated glucose control (AGC) algorithm in one wearable patch. It aims to reduce the burden of managing separate devices for automated insulin delivery (AID).

The study addressed a central integration challenge: maintaining glucose measurement performance when insulin is delivered close to the sensor. Temporary interference after a bolus was uncommon overall and occurred mainly with doses of 10 units or more, where the probability was 20 to 25%. On average, the sensor signal fully recovered approximately 20 minutes after bolus delivery. In the second part of the study, the prototype was also tested together with the AGC algorithm developed by Prof. Ahmad Haidar. The PharmaSens niia patch pump, the SiBionics sensor and the AGC algorithm performed consistently throughout the study. The findings, also featured at the SiBionics booth, mark an early development milestone.

Together, the exhibition and symposium connected clinical needs with emerging technologies. Through niia signature, PharmaSens and SiBionics are exploring how integration could make future AID easier to wear and use. Further research is needed to establish its performance and clinical potential.

niia signature is an investigational device. It is not approved or cleared in any market and is not available for sale.

About SIBIONICS

Founded in 2015 and headquartered in Shenzhen, SiBionics is a medical technology company specializing in CGM and multi-parameter health solutions, with nearly 700 professionals worldwide. Combining advanced sensor technology with AI-driven algorithms, the company develops accessible, reliable solutions for chronic disease management. Its multidisciplinary R&D team brings expertise in biosensing, chip design, materials science, and artificial intelligence, supporting innovation from research to commercialization. Through fully in-house CGM systems and continuous monitoring technologies, SiBionics provides real-time data and comprehensive insights to support daily management and better-informed health decisions. Learn more at www.sibionicscgm.com.

About PharmaSens

PharmaSens AG, a privately owned Swiss company, is dedicated to simplifying diabetes management and broadening the reach of insulin pump therapy. The PharmaSens team has a wealth of experience in diabetes care and medtech device engineering, having contributed to the development of multiple insulin pump generations. Over several years of research and development, PharmaSens has built a patented international portfolio of distinctive and innovative products. For more information, please visit PharmaSens.com.

Media contacts

SIBIONICS: ravian.luo@sibionics.com

PharmaSens: info@pharmasens.com 

Kinmen Kaoliang Liquor Accelerates Global Expansion from Asia into Europe and North America

Talent, Product Innovation and Distribution Advance in Tandem to Bring Taiwanese Baijiu to the World

SEOUL, South Korea and BUSAN, South Korea, Oct. 4, 2026 /PRNewswire/ — Kinmen Kaoliang Liquor (KKL), which has been honing the craft of kaoliang distilling for more than 70 years, is accelerating its international expansion in 2026 by reaching out to younger consumers, diversifying its product portfolio and expanding into new markets.

The 2026 Kinmen Kaoliang Cup professional division brought together 30 top bartenders from across Taiwan to create new interpretations of kaoliang cocktails.
The 2026 Kinmen Kaoliang Cup professional division brought together 30 top bartenders from across Taiwan to create new interpretations of kaoliang cocktails.

KKL has earned accolades at global spirits competitions, invested in bartender training and overseas guest appearances at leading bars, and drawn strong buyer interest at this year’s FHA–Food & Beverage 2026 in Singapore. The show yielded distribution agreements and new customer orders in Malaysia and Singapore, marking tangible progress in Southeast Asia. This October, KKL will join the Taiwan External Trade Development Council (TAITRA) at SIAL Paris 2026, the world’s largest food trade show. For 2027, KKL plans to take part in the Seoul Bar & Spirits Show and host tasting events across Southeast Asia. By advancing on three fronts — talent development, product innovation and distribution — KKL is shifting its overseas efforts from building brand awareness to establishing a lasting market presence.

From Campus to the World’s Bars: Kinmen Kaoliang Cup Builds an International Talent Pipeline

Beyond bringing its products to new markets, KKL is working to put Taiwan’s bartending talent on the international stage. The company’s Kinmen Kaoliang Cup cocktail competition features student and professional divisions, creating a pathway from nurturing emerging talent on campus to industry engagement and international exchange for professional bartenders. In 2026, the top three finishers in the competition’s professional division represented KKL as guest bartenders at leading South Korean bars. Centering their creations on Kinmen Kaoliang Liquor, the trio brought Taiwan’s terroir and contemporary mixology to the international bar scene, giving audiences worldwide a taste of Taiwan’s spirits while showcasing the creative energy of its bartenders.

Their overseas guest appearances are not the end of the journey. After returning to Taiwan, the three bartenders will, for the first time, take their talents on the road as part of the 2026 KK Bar Cocktail Guide—Kinmen Kaoliang Cocktail Guide, making a series of pop-up guest appearances at partner bars across the island. The initiative brings the fruits of international exchange back to the Taiwanese market and invites more consumers to rediscover the distinctive flavors of Kinmen Kaoliang Liquor.

Strong Buyer Interest in Singapore and Exclusive Distributor Secured in Malaysia: From Global Exposure to Commercial Results

At FHA–Food & Beverage 2026 in Singapore, KKL attracted strong interest from international buyers and spirits distributors, securing new orders and partnership leads—an important step in strengthening its Southeast Asian distribution network. Generations ago, many Kinmen residents crossed the seas in search of opportunity, putting down roots and building thriving communities across Singapore, Malaysia and other parts of Southeast Asia. Those deep bonds of kinship, together with a network of Kinmen community associations across the region, now provide a powerful cultural bridge as KKL takes its brand to the world. Word-of-mouth recommendations within these communities, along with local business connections, have greatly accelerated the brand’s expansion into new markets.

Building on its Southeast Asian momentum, KKL is scheduled to join forces with TAITRA and a group of leading Taiwanese food companies as part of a “Team Taiwan” delegation at SIAL Paris, one of the world’s largest food trade shows, this October. The delegation will target opportunities in Western fine dining and premium spirits markets. In 2027, KKL plans to exhibit at the Seoul Bar & Spirits Show, one of Asia’s major professional bar and spirits exhibitions. Building on its existing presence in South Korea and relationships with the country’s bar community, the brand will connect with international bartenders, bar operators, and younger consumers. KKL will also host tasting events across Southeast Asia in partnership with local distributors, deepening its long-term engagement with both the market and consumers in the region.

From Signature Kaoliang Spirit to a Diversified Portfolio: Innovative Flavors for Global Markets

As KKL’s global footprint expands, the distiller is developing innovative products tailored to diverse markets, generations and drinking cultures. Drawing on more than seven decades of kaoliang distilling expertise, KKL has expanded its portfolio beyond its classic Kinmen Kaoliang Liquor. The lineup now includes cask-finished specialty spirits, kaoliang beer, KKL’s own whisky and low-ABV ready-to-drink (RTD) cocktails. With different alcohol strengths and flavor profiles suited to a variety of drinking occasions, KKL is giving consumers worldwide more ways to discover the world of Kinmen Kaoliang—and these innovative releases have already generated a positive response in the market.

According to KKL, international expansion is about more than selling products in more markets. The company is focused on building a lasting and sustainable foundation overseas through talent development, product innovation, and strong distribution networks. Looking ahead, KKL will build on its distilling expertise and continue to expand through international trade shows, distribution partnerships, bartender exchanges, and a diversified product portfolio. The company is committed to helping the world move beyond simply discovering Kinmen Kaoliang Liquor to truly understanding and appreciating it—bringing Taiwanese baijiu, together with Kinmen’s distinctive terroir, craftsmanship and spirit of innovation, to an ever-wider global audience.

Press Materials: https://reurl.cc/jVpG9n 

KKL participated in FHA–Food & Beverage 2026 in Singapore as part of its expansion into Southeast Asian markets.
KKL participated in FHA–Food & Beverage 2026 in Singapore as part of its expansion into Southeast Asian markets.

KKL advances its international brand presence through talent development and international exchange, with the top three finishers in the Kinmen Kaoliang Cup traveling to South Korea for guest appearances at the acclaimed Bar Cham.
KKL advances its international brand presence through talent development and international exchange, with the top three finishers in the Kinmen Kaoliang Cup traveling to South Korea for guest appearances at the acclaimed Bar Cham.

KKL advances its international brand presence through talent development and international exchange, with the top three finishers in the Kinmen Kaoliang Cup traveling to South Korea for guest appearances at the acclaimed Bar Cham.
KKL advances its international brand presence through talent development and international exchange, with the top three finishers in the Kinmen Kaoliang Cup traveling to South Korea for guest appearances at the acclaimed Bar Cham.